CSL Ltd. — Capital/Financing Update 2006

Feb 7, 2006

CSL Limited to Apply for License to Market Influenza Vaccine in the U.S.

Australia's Major Vaccine Manufacturer to Double Capacity

February 8, 2006 - CSL Limited (ASX: CSL), Australia's leading biopharmaceutical company today announced plans to introduce its influenza vaccine into the U.S. market.

Speaking at Merrill Lynch's Global Pharmaceutical and Biotechnology Conference in New York, CSL Chief Executive Officer and Managing Director Dr. Brian McNamee said,

"CSL is the leading producer of influenza vaccine in the Southern Hemisphere and has a long heritage in biological research and manufacture. With the planned expansion of our influenza vaccine production capabilities, we look forward to working with the Food and Drug Administration (FDA) on the licensing of our vaccine in the U.S."

Dr. McNamee announced a \$80 million investment in plant and equipment to double capacity at its Melbourne facility to approximately 40 million doses per season, making it one of the largest vaccine manufacturing plants in the world.

"This will increase the diversity of supply in the U.S., helping to meet the public health need for vaccinations identified by the Centres for Disease Control and Prevention and other policy makers," Dr. McNamee added.

CSL plans to initiate a human clinical study of the vaccine in the US later this year, and submit a Biologics License Application (BLA) to the FDA within 12 months, for both multi-dose vial and thiomersal-free single-dose syringe products. Contingent upon regulatory approval, the company intends to have vaccine available for the 2007-2008 season. The company plans to supply up to 20 million doses to the U.S. as the expanded plant comes online in 2008.

CSL's plan to double its manufacturing capacity will enhance Australia's ability to respond to influenza vaccine demand.

About CSL Limited

Headquartered in Melbourne, CSL Limited (ASX: CSL) is a global, specialty biopharmaceutical company that develops, manufactures and markets products to treat and prevent serious human medical conditions.

$/2...$

CSL has manufactured influenza vaccine in its Melbourne facility since 1968. CSL-branded influenza vaccines are approved and marketed in 16 countries worldwide. The company also provides bulk influenza vaccine for sale in 24 countries. In the United Kingdom, one in four influenza vaccine recipients were vaccinated with a CSL product this season.

For more information about CSL Limited, visit www.csl.com.au.

Media Contacts:

Australia and New Zealand

Dr. Rachel David Director of Public Affairs Phone: 0401 775 779 Email: rachel.david@csl.com.au

Investor Contact:

Mark Dehring Director of Investor Relations Phone: 61 3 9389 2818 Email: mark.dehring@csl.com.au